New Therapeutic Target for Graft-vs-Host Disease Could Make Bone Marrow Transplant Safer

Chronic graft-vs-host disease (GVHD) is a well-known complication of bone marrow transplant that causes widespread fibrosis of the affected organs, potentially leading to loss of organ function. Early phase data suggest that targeting the enzyme Sirt-1 may help control the occurrence GVHD—even after it has developed—in patients with hematologic cancers, without increasing the chance of relapse.

Science Daily